Development of a Janus Kinase (JAK) Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis

While highly efficacious in treating rheumatoid arthritis (RA), the approved JAK inhibitor, Tofacitinib (Tofa, CP-690 550), has dose-dependent toxicities that limit its clinical application. In this study, we have examined whether a prodrug design that targets arthritic joints would enhance Tofa’s t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Pharm
Main Authors: Wei, Xin, Wu, Jianbo, Zhao, Gang, Galdamez, Josselyn, Lele, Subodh M., Wang, Xiaoyan, Liu, Yanzhi, Soni, Dhruvkumar M., Purdue, P. Edward, Mikuls, Ted R., Goldring, Steven R., Wang, Dong
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078779/
https://ncbi.nlm.nih.gov/pubmed/29966420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.8b00433
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados